文献速递系统性红斑狼疮

抑制血清干扰素-γ水平可作为乌司奴单抗治疗系统性红斑狼疮应答的潜在指标

Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2021-02-01

该研究利用一项II期随机安慰剂对照试验的102例活动性SLE患者生物标志物数据,分析乌司奴单抗治疗后细胞因子变化与SRI-4应答的关系。结果显示SRI-4应答与血清IFNγ蛋白水平持续降低显著相关(P < 0.01),而未见于无应答者或安慰剂组,提示IL-12阻断在乌司奴单抗作用机制中起重要作用。

要点

  • 乌司奴单抗治疗SLE的SRI-4应答与血清IFNγ持续降低显著相关(P < 0.01)。
  • IL-17A、IL-17F、IL-22变化与SRI-4应答无一致显著关联。
  • 血清IFNγ降低未见于乌司奴单抗无应答者或安慰剂组患者。

核心结论

  • 乌司奴单抗治疗SLE的临床应答与血清IFNγ蛋白水平持续降低显著相关,提示IL-12阻断在其作用机制中起重要作用。

研究设计与样本

  • II期随机安慰剂对照试验纳入102例自身抗体阳性且标准治疗下仍活动的SLE患者,按3:2随机接受约6 mg/kg乌司奴单抗或安慰剂静脉给药,随后每8周皮下注射90 mg乌司奴单抗或安慰剂,安慰剂组交叉至每8周90 mg乌司奴单抗。

主要发现

  • 治疗后不同时间点血清IL-17A、IL-17F、IL-22水平变化与乌司奴单抗的SRI-4临床应答无一致显著关联。
  • 乌司奴单抗的SRI-4应答与多个时间点相对基线的血清IFNγ蛋白水平持续降低显著相关(P < 0.01),而未见于无应答者或安慰剂组患者。

关键数值与推荐

  • SRI-4应答与血清IFNγ蛋白水平持续降低显著相关(P < 0.01)。

临床怎么用

  • 血清IFNγ水平持续降低或可作为乌司奴单抗治疗SLE的潜在应答生物标志物,辅助判断IL-12阻断的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In a previously reported phase II randomized, placebo-controlled, interventional trial, we demonstrated that treatment with ustekinumab, an anti-interleukin-12 (IL-12)/IL-23 p40 neutralizing monoclonal antibody, improved global and organ-specific measures of disease activity in patients with active systemic lupus erythematosus (SLE). Utilizing the biomarker data from this phase II clinical study, we sought to determine whether modulation of the expression of IL-12, IL-23, or both cytokines by ustekinumab is associated with clinical efficacy in patients with SLE. METHODS: This phase II randomized, placebo-controlled study enrolled 102 patients with autoantibody-positive SLE whose disease remained active despite standard-of-care therapy. Patients were randomized at a 3:2 ratio to receive ~6 mg/kg ustekinumab intravenously or placebo at week 0, followed by subcutaneous injections of 90 mg ustekinumab or placebo every 8 weeks, with placebo crossover to 90 mg ustekinumab every 8 weeks. The SLE Responder Index 4 (SRI-4) at week 24 was used to determine which patients could be classified as ustekinumab responders and which could be classified as nonresponders. In addition to measurements of p40 and IL-23, serum levels of interferon-γ (IFNγ), IL-17A, IL-17F, and IL-22, as a proxy for the IL-12 and IL-23 pathways, were quantified by immunoassay. RESULTS: Changes in the serum levels of IL-17A, IL-17F, and IL-22 at different time points after treatment were not consistently significantly associated with an SRI-4 clinical response to ustekinumab in patients with SLE. In contrast, an SRI-4 response to ustekinumab was significantly associated (P < 0.01) with durable reductions in the serum IFNγ protein levels at several time points relative to baseline, which was not observed in ustekinumab nonresponders or patients who received placebo. CONCLUSION: While not diminishing a potential role of IL-23, these serum biomarker assessments indicate that IL-12 blockade has an important role in the mechanism of action of ustekinumab treatment in patients with SLE.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Cesaroni M, Seridi L, Loza MJ, et al. Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2021. PMID: 33010188. doi:10.1002/art.41547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。